• Troglitazone as a PPARγ Agonist: Workflows & TAM Modulation

  2026-08-04

  Troglitazone's dual PPARγ/α agonism bridges metabolic and immuno-oncology research, enabling precise modulation of lipid metabolism and tumor microenvironments. This article unpacks workflow innovations, troubleshooting, and advanced applications for harnessing Troglitazone in SPP1/TAM-targeted studies, with evidence-driven protocol parameters.

• EZ Cap™ Human PTEN mRNA: Redefining Tumor Suppressor Restora

  2026-08-04

  Explore how EZ Cap™ Human PTEN mRNA advances tumor suppressor gene research with Cap 1 mRNA design and poly(A) tail stability. This in-depth review reveals practical insights for optimized cancer and gene therapy workflows.

• CKI 7 dihydrochloride: Precision Casein Kinase 1 Inhibitor W

  2026-08-03

  CKI 7 dihydrochloride stands out as a selective Casein kinase 1 inhibitor, empowering researchers to dissect intricate pathways such as Wnt/β-catenin and circadian rhythm regulation. This guide delivers actionable workflows, troubleshooting strategies, and translation of recent cancer metastasis findings into robust experimental design.

• Bacillus Strains and Media Drive γ-Glu-Cys Peptide Productio

  2026-08-03

  This study delineates how Bacillus species and growth media composition influence the generation of γ-glutamyl peptides, with a focus on the critical intermediate gamma-Glu-Cys (γ-Glu-Cys). The findings highlight medium selection as a primary determinant of peptide yield, informing optimized strategies for glutathione metabolism research and food bioprocessing.

• Crizotinib hydrochloride: ALK Kinase Inhibitor for Cancer Re

  2026-08-02

  Crizotinib hydrochloride is a potent ATP-competitive ALK kinase inhibitor used in cancer biology research. It demonstrates high efficacy in inhibiting ALK and c-Met phosphorylation at low nanomolar concentrations, supporting advanced organoid and assembloid models. APExBIO supplies this compound at research-grade purity for robust preclinical workflows.

• RNA Pol II Degradation Triggers Apoptosis Beyond Transcripti

  2026-08-01

  Harper et al. (2025) demonstrate that inhibition of RNA polymerase II (Pol II) triggers regulated cell death through a specific apoptotic pathway, independent of global transcriptional shutdown. This discovery reshapes our understanding of cell death mechanisms in cancer research and has implications for the evaluation of apoptosis assays and targeted therapies.

• Applied Use of Thiamet G: O-GlcNAcase Inhibitor in Bone & Ne

  2026-07-31

  Thiamet G, a potent O-GlcNAcase inhibitor, enables precise and robust modulation of O-GlcNAcylation for dissecting cellular pathways in neurodegeneration and bone anabolism. This guide decodes optimized protocols, troubleshooting strategies, and translational advantages, with direct application to the latest breakthrough on Wnt-driven bone formation.

• Single Dose Indometacin Sodium for Acute Postoperative Pain

  2026-07-31

  The referenced Cochrane systematic review rigorously examines the efficacy and safety of a single oral dose of indometacin sodium for managing acute postoperative pain. This evidence synthesis clarifies its analgesic performance compared to other NSAIDs and informs dosing strategies relevant for both clinical and experimental inflammation research.

• Distinct Pathways in Penile Urethral Development: Insights f

  2026-07-30

  This study provides a comparative analysis of penile development in guinea pigs and mice, revealing that distinct patterns of Shh, Fgf10, and Fgfr2 expression underlie species-specific differences in urethral groove and prepuce formation. The findings offer new mechanistic insights relevant for developmental biology and teratogenicity research.

• Spliceosome Acetylation Alters PARP Inhibitor Sensitivity in

  2026-07-30

  This study reveals that acetylation-dependent regulation of the spliceosome core component SmD2 modulates alternative splicing and DNA repair in hepatocellular carcinoma (HCC). The findings provide a mechanistic rationale for combining PARP inhibitors with HDAC inhibition in HCC, offering new opportunities for targeting DNA repair deficiencies beyond BRCA-mutant tumors.

• PF-573228: Potent FAK Inhibitor for Mechanotransduction and

  2026-07-29

  PF-573228 is an ATP-competitive FAK inhibitor with nanomolar potency, enabling precise interrogation of FAK signaling in cancer and tissue engineering. This dossier outlines its mechanism, benchmarks, and practical limits for anti-angiogenic and cell migration research.

• Ganetespib (STA-9090): Precision Hsp90 Inhibition in Advance

  2026-07-29

  Discover how Ganetespib (STA-9090) redefines Hsp90 inhibition for cancer research, offering unique mechanistic insights and practical assay guidance. This article delivers a fresh, scientifically rigorous perspective that goes beyond current literature.

• Dehydroabietic Acid: Dual PPAR-α/γ Agonist for Metabolic Res

  2026-07-28

  Dehydroabietic acid is a high-purity, dual PPAR-α/γ agonist that modulates lipid metabolism and insulin sensitivity. This compound, available from APExBIO, is validated for advanced metabolic disorder research and features robust solubility in DMSO and ethanol. Its precise action and stringent quality controls make it ideal for reproducible experimental design.

• IWP-2: Advanced Wnt Production Inhibitor Protocols for Cance

  2026-07-28

  IWP-2, a potent Wnt production inhibitor from APExBIO, empowers researchers to precisely disrupt Wnt/β-catenin signaling in cancer, tissue engineering, and cell culture paradigms. This guide unpacks actionable workflows, troubleshooting strategies, and cross-domain insights for leveraging IWP-2 in high-impact experimental systems.

• Escitalopram in Experimental Psychiatry: From Molecular Sele

  2026-07-27

  Explore Escitalopram's unique selectivity and translational value in antidepressant research. This article goes beyond protocol basics, revealing assay design nuances and the real-world impact of recent clinical findings.

15745 records 1/1050 page Next 12345 下5页 Last page